NeoVirTech

NeoVirTech is a French biotechnology company and contract research organization (CRO) specializing in the development of autofluorescent viruses and viral vectors for imaging, antiviral discovery, and disinfection testing. The company's proprietary ANCHOR™ technology is a non-invasive, live-cell imaging platform that allows real-time visualization and quantification of viral infection, replication, and propagation without the need for cell fixation or staining. Beyond its CRO services, NeoVirTech is advancing its own therapeutic pipeline, including LAVR-289, a preclinical broad-spectrum acyclic nucleoside phosphonate prodrug that targets viral DNA polymerase to treat adenovirus, herpesvirus, and poxvirus infections. Additionally, the company is developing a DNA origami-based oncology platform for targeted delivery of immunostimulatory payloads to solid tumors, and is leading the France 2030-funded 'Perseverance' program to accelerate the preclinical development of oncolytic viruses.